The Ozempic Paradox (opens in new tab)

The Ozempic Paradox by Alan Cassels at Brownstone Institute Here’s a good current example of medical irony: the same week that our drug regulator, Health Canada, approved the first generic version of semaglutide—the active ingredient in weight-loss drug Ozempic—a major medical journal published findings highlighting the medication's troubling connection to eating disorders. The timing couldn't be more paradoxical: just as this powerful appetite suppressant becomes more accessible and affordab...